Fig. 1From: A comparative clinical study of PF-06410293, a candidate adalimumab biosimilar, and adalimumab reference product (Humira®) in the treatment of active rheumatoid arthritisStudy design. Abbreviations: Adalimumab-EU adalimumab sourced from the European Union, EOT end of treatmentBack to article page